Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Lactobacillus reuteri DSM 17938 and Reduced Use of Pain Relieving Drugs

Doses used in studies

CFU single-dose: 200 million (median 200 million, IQR 200 million–200 million) — 1 study

Time to effect

Median: 4 weeks · IQR 4 weeks–4 weeks · Range 4 weeks–4 weeks — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
No side effects were recorded.
from: Lactobacillus reuteri DSM 17938 and a placebo both significantly reduced symptoms in child

1 of 1 paper

Lactobacillus reuteri DSM 17938 and a placebo both significantly reduced symptoms in children with functional abdominal pain.
- 2017-08-22
- RCT · n = 54
- Acta paediatrica (Oslo, Norway : 1992) 106(11)
- - M Maragkoudaki
  - G Chouliaras
  - R Orel
  - A Horvath
  - H Szajewska
  - A Papadopoulou
- PubMed: 28712129
- DOI: 10.1111/apa.13992
5 Insights on
- Reduced Use of Pain Relieving Drugs
- High evidence
- Clinical
L. reuteri decreased the use of pain relieving drugs at four weeks… unlike the placebo, which achieved nonsignificant results. However, the difference between the groups did not reach significance.
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
2 × 10^8 colony-forming units